The downregulation of tyrosine kinase receptors attenuates signalling and is thought to be dependent upon intrinsic receptor kinase activity, largely because downregulation is inhibited by a kinase-inactivating mutation of an invariant lysine residue of the receptors for EGF, insulin, M-CSF and PDGF. We con®rmed that this mutation inhibited the degradation of the M-CSF receptor. However, two dierent kinase inactivating mutations of the invariant amino acids Gly 591 and Glu 633 did not prevent M-CSF-induced receptor degradation, so demonstrating that receptor kinase activity is not essential for this process. Three other kinase-inactivating mutations were found to cause constitutive receptor degradation in the absence of M-CSF, most probably by disrupting the structure of the activating loop of the kinase domain. It is known that extensive movement of the A-loop is necessary for kinase activation and is normally induced by ligand-binding. It is therefore suggested that some aspect or consequence of the change in structure of the A-loop caused by ligand binding also activates receptor downregulation, so ensuring that downregulation is coupled to but is not necessarily dependent upon receptor kinase activity.
Introduction
The binding of growth factors to receptors usually causes the internalization and degradation of the receptor-ligand complex, a process referred to as receptor downregulation (Opresko et al., 1995; Seaman et al., 1996) . Receptor downregulation is important because it attenuates signalling, as shown by the ®nding that mutant receptors for EGF and PDGF that are resistant to ligand-induced degradation have ampli®ed mitogenic activity (Wells et al., 1990; Mori et al., 1993) .
The binding of EGF causes EGF receptors to dimerize and concentrate in clathrin-coated pits for eventual delivery to lysosomes where the ligand:receptor complexes are degraded (Seaman et al., 1996) . Certain receptors such as the insulin receptor are internalized within clathrin coated vesicles but may then dissociate from insulin within the endosomes and recycle to the cell surface (Carpentier, 1994) . A number of growth factor receptors are ubiquitinated as a result of ligand binding and there is evidence that ubiquitination is important for down-regulation of the receptors for growth hormone and for PDGF (Strous et al., 1996; Mori et al., 1993) . It has been suggested that ubiquitination may regulate the degradation of some receptors by either lysosomes or proteasomes (Hicke, 1997) .
Downregulation of the receptors for EGF (Honneger et al., 1987; Glenney et al., 1988) , insulin (Russell et al., 1987; McClain et al., 1987; Hari and Roth, 1987) , M-CSF (Downing et al., 1989; Carlberg et al., 1991) and PDGF (Sorkin et al., 1991 ) is thought to be dependent upon intrinsic receptor tyrosine kinase activity, largely because both processes are inhibited by mutation of an invariant lysine residue of the b3 strand ( Figure 1a ). In support of this, multiple mutations of tyrosine autophosphorylation sites within the carboxyl terminus of the EGF receptor also inhibit downregulation (Sorkin et al., 1992) as do mutations of autophosphorylation sites within the activating loop of the kinase domain of the insulin receptor (Carpentier, 1994) .
It is not clear why kinase activity is essential for the downregulation of tyrosine kinase receptors, particularly as receptors without intrinsic kinase activity are also downregulated (Strous et al., 1996) . It has been suggested that downregulation of the M-CSF receptor is dependent upon substrate phosphorylation (Carlberg et al., 1991) . A dierent model is that autophosphorylation of the EGF receptor stabilizes a change in its structure that exposes cryptic internalization and degradation sites (Opresko et al., 1995) .
There is some evidence against the requirement of receptor tyrosine kinase activity for downregulation. Backer et al. (1989) showed that the inhibition of insulin receptor autophosphorylation by treatment with 2,4-dinitrophenol does not inhibit receptor internalization. Livneh et al. (1987) demonstrated that a mutant EGF receptor that is kinase-defective due to a four amino acid insertion into the conserved Gly-rich loop (Figure 1 ) is normally degraded in response to EGF and so they concluded that receptor kinase activity is not necessary for downregulation. However, some of the same authors concluded the opposite from their study of a kinase-defective EGF receptor with a mutation of the invariant Lys 721 residue (Honneger et al., 1987) . Glenney et al. (1988) discussed whether the contradictory results of Livneh et al. (1987) and Honneger et al. (1987) might be due to dierences between cell lines or between the amount of endogenous EGF receptor expression.
A number of authors have discussed the possibility that mutation of the invariant lysine residue might inhibit receptor downregulation because of possible eects upon receptor structure rather than inhibition of kinase activity (Russell et al., 1987; Backer et al., 1989) . We have therefore looked at the downregulation of six dierent kinase-defective M-CSF receptors expressed in similar amounts in the same cell line in the absence of endogenous receptor expression. Figure 1a shows the single amino acid changes that were separately introduced by oligo-directed mutagenesis to give six dierent kinase-defective M-CSF receptors. One of the receptors has a previously described kinase inactivating mutation of an invariant lysine residue at position 616 (Downing et al., 1989; Carlberg et al., 1991) . The sequences of cAPK and the insulin receptor kinase are shown for comparison. Four other single invariant amino acids that are known to be critical for kinase activity (Gibbs and Zoller, 1991; Taylor et al., 1992) were also altered ( Figure 1a) . The sixth mutant receptor has a previously described kinase inactivating mutation of tyrosine 809 (van der Geer and Hunter, 1991) , which is an autophosphorylation site at an equivalent position of phosphothreonine 197 of cAPK (Figure 1a) .
Results
Each of the receptors was expressed in Rat-2 ®broblasts following retroviral infection. Figure 1b (not shown) also revealed the faint presence of these bands for each of the mutant receptors, indicating that they retained barely detectable levels of residual activity. The mutant receptors were also defective for the phosphorylation of peptide substrates (data not shown). Each of the kinase mutations prevented foci formation by Rat-2 ®broblasts and the proliferation of the haemopoietic cell line FDC-P1 in response to M-CSF (data not shown) so con®rming the importance of these invariant residues for kinase activity and for signalling. Figure 1c shows a Western blot of M-CSF receptors present in 200 mg of the same total protein lysates that were used in Figure 1b . This blot con®rms that the dierent receptors were expressed at similar levels in Figure 1b and it also shows that two of the mutant receptors R900A (lane 3) and E825K (lane 5) had a reduced level of mature receptor and an increased amount of immature receptor. This result was consistently reproduced and indicated that these mutant receptors were impaired for the processing of the immature to mature form. Figure 1d is a Western blot of M-CSF receptors expressed at the cell surface of Rat-2 ®broblasts. Intact cells were ®rst biotinylated for 15 min in order to label cell surface proteins only. The biotinylation reaction was quenched and then M-CSF receptors were immunoprecipitated and biotinylated receptors were detected by Western blotting using streptavidin-HRP. Because the immature receptor is not expressed at the cell surface, only the mature wild type receptor was detected ( Figure 1d Figure 2b show that M-CSF did not, as expected, enhance the degradation of the kinase-defective receptor with a mutation of Lys 616 to alanine. However, a comparison of lanes 2 and 3 of Figure 2c and d shows that M-CSF did enhance the degradation of two dierent kinase-defective receptors with mutations of Gly 591 to Ala and Glu 633 to His. Comparison of lanes 2 and 3 of Figure 2f and g shows that M-CSF did not noticeably enhance the degradation of the two kinase-defective receptors with mutations of the highly conserved residues Glu 825 and Arg 900. However, these receptors had slightly reduced levels in the absence of M-CSF compared to normal (compare lanes 1 and 2 of Figure 2a, f and g ), indicating that their degradation might be constitutively activated by their kinase inactivating mutations. (Figure 1a) . The previously described kinase-defective receptor Y809G (van der Geer and Hunter, 1991; Figure 1a ), was also included in this analysis and showed clearer evidence of constitutive degradation (compare lanes 1 and 2 of Figure 2a and e). Figure 3 shows the results of a more detailed pulse chase analysis of the wild type M-CSF receptor and three representative kinase-defective receptors. The receptors were labelled for 3 h with 35 S-methionine (Figure 3, lanes 1 and 6) and then chased with cold methionine for 1, 2, 3 and 4 h in the absence (lanes 2 ± 5) or presence of M-CSF (lanes 7 ± 10). In the absence of M-CSF the mature form of the normal receptor evident in lane 1 (Figure 3a ) disappeared with a half (Figure 3a and e and data not shown), indicating that the receptor was turned over in the absence of M-CSF, as expected (Rettenmier et al., 1987) . The addition of M-CSF markedly enhanced its turnover, also as expected (Rettenmier et al., 1987) . The degradation of the K616A mutant receptors was not enhanced by the addition of M-CSF although these receptors were still turned-over in its absence ( Figure  3b and f), as expected (Downing et al., 1989) . In our system the K616A receptors were more stable than the normal receptor in the absence of M-CSF. The turnover of the kinase-defective receptor E633H was evidently enhanced by the addition of M-CSF ( Figure  3c and g ). The degradation kinetics of the normal and mutant E633H receptors were very similar in the presence of M-CSF. In the absence of M-CSF the mutant receptor was slightly more unstable. Figure 3d and h show that the turnover of the kinase-defective R900A mutant receptor was unaected by M-CSF addition. However, the degradation pro®le was very dierent to that of K616A, which was also resistant to M-CSF-induced degradation (compare Figure 3f and h). The longer time points reveal that in the absence of M-CSF the mature form of the R900A receptor was less stable than the mature form of the normal receptor (compare lanes 3, 4 and 5 of Figure 3a and d) , so con®rming the results of Figure 2 . At earlier time points this feature was disguised by the slower than normal processing of the immature protein which added to the amount of mature protein over a longer period of time than normal. Identical results were obtained on at least three other occasions for R900A and similar results were consistently obtained for the mutant E825K receptor (Figure 2 and data not shown).
Discussion
Mutation of Lys 616 was the only one of six kinase inactivating mutations that clearly inhibited the degradation of the M-CSF receptor in response to M-CSF. Therefore these results do not support the previous conclusions that M-CSF-induced degradation is dependent upon receptor autophosphorylation or upon substrate phosphorylation (Downing et al., 1989; Carlberg et al., 1991) . These results also raise doubts about some of the conclusions from studies of the downregulation of other receptors that used equivalent lysine mutant receptors (see Introduction) and emphasize the importance of using more than one mutation to test for the dependence of receptor function upon kinase activity.
The mutant K616A receptor was processed normally from the immature to the mature form and was expressed properly at the cell surface (Figures 1 and  3) , which is consistent with previous reports that this mutant receptor and equivalent EGF and insulin mutant receptors have not suered any gross changes of structure (Russell et al., 1987) . Nevertheless, mutation of the equivalent Lys of yeast cAPK is one of the more disruptive of the kinase inactivating mutations because it impairs all three measured parameters of kinase activity namely, ATP binding, peptide substrate binding and k cat (Gibbs and Zoller, 1991) . The wide ranging inhibitory eect of this mutation upon kinase activity indicates a structural eect. In support of this, crystallographic data shows that the invariant Lys residue of kinases interacts with both ATP and with the invariant Asp residue at the beginning of the activating loop (D184 of cAPK, Figure 1a ) when the kinase is inactive and with the invariant Glu residue of the C helix (E91 of cAPK) upon kinase activation (Jerey et al., 1995) . Consequently, mutation of the invariant Lys residue would be expected to have structural consequences.
The kinase inactivating mutations studied here divided into three groups. The Lys 616 mutation, which inhibited ligand-induced degradation; the E633H and G591A mutations which did not; and the Y809G, E825K and R900A mutations which constitutively activated receptor degradation. The degradation of the E633H and G591A mutant receptors in response to M-CSF was similar to the normal receptor. The straightforward interpretation of this observation is that both the normal and mutant receptors can be downregulated by a ligand-induced change in receptor structure that is independent of receptor kinase Figure 4 The inactive backbone structure of the insulin receptor (Hubbard et al., 1994) showing the location of the indicated amino acids. The activating loop residues 1150 ± 1179 are shown in black. Residues G1005, K1030, E1047, D1156, Y1163, E1179 and R1253 are equivalent to residues G591, K616, E633, D802, Y809, E825 and R900 of the M-CSF receptor (Figure 1 ). (b) Space®ll model of residues Glu 1179 of the activating loop and Arg 1253 illustrating their interaction activity. Both lysosomal degradation and ubiquitination are implicated but are not established to have critical roles in the downregulation of the M-CSF receptor (Myles et al., 1994; Stanley et al., 1997) . The mutant G591A and E633H receptors may possibly be downregulated by a dierent pathway to normal, however, it would have to be an M-CSF-dependent default pathway which seems unlikely. It also seems unlikely that possible minor dierences in residual kinase activity could explain the widely dierent degradation pro®les of the various kinase-defective mutant receptors (Figure 1b and 3) . These results do not rule out an augmentory role for M-CSF receptor kinase activity in downregulation.
The Y809G, E825K and R900A mutant receptors described here can be considered part of a larger group which includes four other receptor mutants that are also actively degraded (Imamura et al., 1994; Formisano et al., 1994; Glover et al., 1995) . Imamura et al. (1994) , identi®ed two kinase inactivating mutations of the insulin receptor that accelerate their degradation and so cause insulin resistance in patients. One of the insulin mutations substitutes Asp for Glu 1179 which is equivalent to Glu 825 of the M-CSF receptor studied here and so is consistent with our results. The second mutation substituted Leu for Trp 1193, which is highly conserved and equivalent to Trp 222 of cAPK ( Figure  4a ). The only other mutation of the insulin b-subunit, as far as we are aware, that accelerates insulin receptor internalization substitutes Gln for Arg 1164 (Formisano et al., 1994; Figure 4a ).
The immature forms of E825K and R900A M-CSF receptors are stable (Figure 1c, 2 and 3) , which perhaps indicates that the mature receptor form is routed for degradation from a cell compartment that is not accessible to the immature form. Imamura et al. (1994) have discussed the possibility that the mutant insulin receptors are degraded by a default pathway, perhaps because they are more susceptible to intracellular proteases. However, these mutations must be particularly adept at inducing receptor degradation because the vast majority of naturally occurring mutant insulin receptors are not actively degraded (Krook and O'Rahilly, 1996) . The E825K and R900A mutant M-CSF receptors are impaired for processing (Figures 1 and 3 ), but this is unlikely to be the reason why they are actively degraded because abnormalities in processing have been reported for other insulin and M-CSF receptor mutants that are not actively degraded (Imamura et al., 1994; Roussel et al., 1988) and because the actively degraded insulin receptor mutants are not impaired for processing (Imamura et al., 1994) .
Remarkably, the insulin and M-CSF receptor mutations that activate degradation all aect a discrete region of the kinase domain (Figure 4) . Two of the three mutant M-CSF receptors that are constitutively degraded (Y809G and E825K) have single amino acid changes within the activating loop (A-loop) of the kinase domain (Figure 4a ). The third mutant receptor R900A has a mutation of an arginine residue that is outside the A-loop but has a highly conserved charged interaction with Glu 825 which is within the A-loop (Figure 4a and b) . In addition, we have previously described a transforming mutation (cfmsD802V) of the A-loop which also causes constitutive receptor degradation (Glover et al., 1995) . Therefore, the four known mutations that activate M-CSF receptor degradation all aect the A-loop. Two of the three insulin mutations that cause receptor degradation (E1179D and R1164Q) also alter amino acids within the A-loop (Figure 4a ). The third W1193L mutation is outside the A-loop but both Trp1193 and Glu 1179 make van der Waals contact with the highly conserved Ala 1177, which is within the A-loop of the insulin receptor (Hubbard et al., 1994) .
All of the mutations that activate receptor degradation would be expected to alter the structure of the Aloop signi®cantly, strongly indicating that degradation is activated for this reason. Mutations of Glu 825 or Arg 900 of the M-CSF receptor and of Glu 1179 of the insulin receptor disrupt a highly conserved salt-bridge (Figure 4b ) which would be expected to unhinge the Aloop region; mutation of Trp 1193 of the insulin receptor may well have a similar eect. The cfmsD802V mutation and the R1164Q insulin receptor mutation are both kinase-activating and must therefore induce considerable movement of the A-loop region (Glover et al., 1995; Formisano et al., 1994) . Substitution of Gly for Tyr 809 of the M-CSF receptor would be expected to introduce increased exibility into this region, particularly if Tyr 809 has a key structural role which seems likely.
It is known that the A-loop must undergo a large change in conformation for kinase activation to occur (Johnson et al., 1996) . Consequently, it is suggested that downregulation of the M-CSF receptor and of tyrosine kinase receptors in general is normally initiated by some aspect or consequence of the change in conformation of the A-loop that is induced by ligand-binding. Such a mechanism would ensure that receptor downregulation is coupled to but is not necessarily dependent upon receptor kinase activation. It is suggested or predicted that mutation of Lys 616 of the M-CSF receptor inhibits degradation by preventing the structural alteration of the A-loop necessary for downregulation whereas the kinase-inactivating mutations of Gly 591 and Glu 633 do not prevent this change.
It has previously been suggested that EGF receptor degradation is initiated by structural changes of the receptor that are stabilized by autophosphorylation and expose cryptic internalization and degradation sites (Opresko et al., 1995) . Our results for the M-CSF receptor are largely consistent with this model except that autophosphorylation was not found to be critical, it may also not be critical for downregulation of the EGF receptor (Livneh et al., 1987) . The challenge now is to identify the critical structural changes of the M-CSF receptor that initiate downregulation and to link these to the ensuing cellular routing pathways.
Materials and methods

Mutant receptor construction
The amino acid changes of the M-CSF receptors detailed in Figure 1a were made by oligo-directed mutagenesis in M13 using the following oligonucleotides: G591A ± CTCGGAGC-TGCTGCCTTTGGG; K616A ± GGTGGCTGTGGCGAT-GCTGAAGT; E633H ± CTCATGTCCCACCGTAAGATC-ATG; Y809G ± GACTCCAACGGCATTGTCAAG; E825K ± ATGGCCCCAAAGAGCATCTT; R900A ± CCCACCCA-CGCTCCCACCTTC. The mutations were subcloned into the retroviral expression vector VSN2c-fms containing the complete cDNA of human c-fms, which encodes the receptor for M-CSF (Sherr et al., 1985; Dibb et al., 1990) .
Retroviral infections
The retroviral packaging cell line C 2 was calcium phosphate transfected with the various vsn2c-fms constructs and the retroviral supernatant was then used to infect Rat-2 ®broblasts which were then selected with G418 (Glover et al., 1995) . This approach gives very uniform levels of receptor expression because the majority of infected cells contain a single provirus (Dibb et al., 1990) .
Receptor analysis
Kinase activity was measured by immunoprecipitation of M-CSF receptors from 5610 6 cells followed by in vitro labelling with gATP as previously described (Glover et al., 1995) . For tyrosine kinase substrate assays, 1 mg of 1 : 4 poly Glu/Tyr (Sigma) was incubated with the immunoprecipitates during the reaction. Steady state receptor levels were measured by Western blotting (Dibb et al., 1990) . Pulse chase experiments were as previously described (Glover et al., 1995) except that human recombinant M-CSF provided by Chiron (Emeryville, CA, USA) with a speci®c activity of 5 6 10 7 units per mg (Ladner et al., 1987; Halenbeck et al., 1989 ) was added to a ®nal concentration of 5000 U/ml. Cell surface expression of M-CSF receptors was assessed by biotinylation under conditions that only label cell surface proteins (Meier et al., 1992) . Intact cells were biotinylated, the reaction was stopped and M-CSF receptors were immunoprecipitated and any biotinylated receptors were detected by Western blotting with a streptavidin:horseradish peroxidase conjugate as previously described (Glover et al., 1995) .
